Commander, U.S. Navy Region Korea Logo Commander, U.S. Navy Region Korea
Commander, Navy Installations Command
  Find Your Region or Installation

COVID-19 Vaccine Information

Quarantine button
Quarantine Process

COVID-19 Vaccine Update

 

Out of an abundance of caution and in accordance with DoD guidance, CNFK, CNRK and CFAC will cancel our administration of the J&J COVID-19 vaccines as was previously planned.

As more information and guidance becomes available we will provide updated information regarding future vaccine efforts and events. Until then, please remember to follow the Core Tenets - Protect Others, Protect Your Bubble, and Protect Yourself. Wear a mask, adhere to ROK government social distancing guidance, and HPCON-B guidance.

Quick Links

 

Chief of Naval Operations Adm. Gilday

“The nation and the Department of Defense are beginning to administer vaccines for the SARS-CoV-2 virus. These vaccines, which are currently voluntary, are a proven effective measure to better protect you, our Navy and our Nation from this insidious threat."

- Chief of Naval Operations (CNO) Adm. Mike Gilday

 

 

 

BACKGROUND

 

The Department of Defense COVID-19 vaccine plan will implement a standardized and coordinated strategy for prioritizing, distributing, administering, COVID-19 vaccine(s) through a phased approach to vaccinate all Active component, Reserve component, TRICARE Prime and TRICARE Select beneficiaries, and select DoD civilians and contract personnel authorized to receive immunizations from DoD. We remain committed to our priorities during the COVID-19 pandemic to protect our people, maintain readiness, and support the national COVID-19 response.

Back to top

Fact Sheets

 

OPERATION WARP SPEED

 

Operation Warp Speed’s goal is to produce and deliver 300 million doses of safe and effective vaccines with the initial doses available by January 2021, as part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.

OWS is a partnership among components of the Department of Health and Human Services (HHS), including the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), and the Department of Defense (DoD). OWS engages with private firms and other federal agencies, including the Department of Veterans Affairs. It will coordinate existing HHS-wide efforts, including the NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership, NIH’s Rapid Acceleration of Diagnostics (RADx) initiative, and work by BARDA.

CBS News Operation Warp Speed Report and interview with U.S. Army Gen. Gus Perna

COVID-19 VACCINE INFORMATION

 

U.S. Navy COVID-19 Vaccine Guidance

The Navy issued COVID-19 Vaccine guidance to combat the coronavirus pandemic with

NAVADMIN 327/20 Dec. 16. This guidance amplifies Department of Defense (DOD) guidance for COVID-19 vaccination to service members, civilians and dependents within the Navy.

All Navy personnel are encouraged to take the vaccine to protect their health, their families, their community, and lower the public health risks associated with the COVID-19 pandemic.

The vaccine is voluntary while under Federal Drug Administration (FDA) Emergency Use Authorization (EUA) approval.

See the link below for the NAVADMIN:

NAVADMIN 327/20

Johnson & Johnson Janssen COVID-19 Vaccine

Johnson and Johnson Banner

MODERNA COVID-19 Vaccine

All eligible USFK-affiliated individuals will be offered the Moderna COVID-19 vaccine, and while it is voluntary and ultimately your choice to receive it, USFK wants you to make an informed and educated decision about the vaccine.

See the fact sheets below for more information regarding the Moderna COVID-19 Vaccine:

FDA COVID-19 Vaccination Information

 

Frequently Asked Questions

 

Moderna COVID-19 Vaccine Frequently Asked Questions
Centers For Disease Control COVID-19 Vaccine Frequently Asked Questions
Food and Drug Administration COVID-19 Vaccine Frequently Asked Questions

Food and Drug Administration COVID-19 Vaccine Frequently Asked Questions

 

General Frequently Asked Questions

 

Q. Why should I get the vaccine?

A. Getting vaccinated can help prevent getting sick with COVID-19

While many people with COVID-19 have only a mild illness, others may can have serious, life-threatening complications get a severe illness or they may even die. There is no way to know how COVID-19 will affect you and, even if you are not at increased risk of severe complications, we don’t fully understand the long term consequences of infection. COVID-19 vaccination may help protect you by creating an antibody response without having to experience the infection.

COVID-19 vaccination will likely be a safer way to help build protection COVID-19 can have serious, life-threatening complications, and there is no way to know how COVID-19 will affect you, or the long term consequences of infection. There is mounting evidence that infections result in at least some duration of protection against reinfection or severe symptoms for approximately 3 months after infection. However, gaining that type of natural protection comes with risks of serious complications and potentially death. Vaccinations offer a controlled and largely very safe way to prepare your immune system to protect you from future infections.

COVID-19 vaccination will be an important tool to help stop the pandemic.

 

Q. What additional privileges will I have once I receive my vaccine i.e. travel and no mask wear?

A. There will be no additional recreational privileges given to anyone receiving the vaccine. It will be crucial for all USFK-affiliated personnel to continue to adhere to the core tenants to ensure the readiness and safety of everyone. 

 

Q. Will we still need to wear masks and practice physical distancing once a vaccine is available?

A. Yes. The intent of the vaccine is to prevent the spread of COVID 19. We will still need to wear cloth face covings and practice physical distancing to limit the spread of the virus. Additionally, we will not have enough vaccine initially to vaccinate everyone who wants the vaccine and COVID-19 pandemic risks will continue. We will continue to recommend wearing masks and practicing physical distancing, for everyone, until pandemic risk of COVID-19 is substantially reduced.

 

Q. What has DoD done to ensure the vaccine(s) they are distributing is safe?

A. Vaccines and therapeutics to prevent and treat diseases are developed in stages. In Phase 1 Trials researchers test an experimental drug or treatment in a small group of people for the first time. In Phase 2 Trials the experimental drug or treatment is given to a larger group of people to see if it is effective and to evaluate its safety further. In Phase 3 Trials the experimental study drug or treatment is given to very large groups of people. Researchers confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug or treatment to be used safely. Manufactures are required to submit their raw data for the FDA to review. Safety, immune response, and efficacy data from the trial stages are submitted to the FDA before they are authorized for use and distribution.

 

Q. Will vaccines be available at Military Treatment Facilities? When will they be available?

A. DoD initially expects limited quantity and a phased delivery of COVID-19 vaccine following FDA Emergency Use Authorization. Initial DoD distribution sites were selected by the DoD’s COVID Task Force from sites recommended by the military services and U.S. Coast Guard to best support several criteria: anticipated supply chain requirements for initially approved vaccines (i.e. ultra-cold, bulk storage facility); sizeable local population to facilitate rapid vaccine administration to priority personnel across the military services; and sufficient necessary medical personnel to administer vaccines and actively monitor vaccine recipients after initial and second-dose administration. Initial vaccine doses will become available at select locations in late 2020 and early 2021, and at additional sites in spring 2021.

 

Q. Can someone get COVID-19 from the vaccine?

A. No, it is not possible to get COVID-19 from vaccines. Vaccines against COVID-19 use inactivated virus, parts of the virus, or a gene from the virus. None of these can cause COVID-19.

 

Q.  Why should we receive the first-available vaccine when there are several other vaccines still in trials?

A. People who are offered the first-available vaccine are considered to be in groups that are most in need of COVID-19 protection. Vaccinated people will be protecting themselves, as well as their families and all people with whom they interact. Evaluation of the first-available vaccine will continue, even after its pre-licensure release. The release of other vaccines cannot be fully predicted, so people who are offered the first-available vaccine will be encouraged to receive this vaccine.

 

Q. Should children get the vaccine?

A. The current vaccine trials have not studied the safety and efficacy for children and manufactures are not currently asking the FDA for authorization to vaccinate children.

 

Q.  How long will protection last following vaccination?

A. We do not know how long protection will last following vaccination but it will be critically important to measure long-term protection (at least two years) in the phase 3 trials and in other groups prioritized for early vaccination. We are still learning about the duration of protection following infection with COVID-19 and it is too early to tell how long protection will last.

 

Q. If I already had COVID-19, should I still get a vaccine?

A. Yes, because duration of immunity following COVID-19 infection is unknown, and the vaccine may be effective in protecting previously infected people. 

 

Q. Should I get the vaccine for influenza (flu shot)?

A. Yes, it is very important to get the influenza vaccine, particularly this season when both influenza viruses and COVID-19 will infect people.

 

Q. The vaccines are being distributed by service. How do I know I’m being considered if I am on a different service’s installation?

A. Each installation Military Treatment Facility will be working with service components to ensure that members across the peninsula are being tracked and prioritized based on their mission. If a member has any questions, they can contact their PCM or chain of command to ensure they have been accounted for.

 

Q. Who will get access to the vaccine first?

A. USFK will be in line with DOD and CDC recommendations to develop the plans and infrastructure for distribution before the vaccine is approved or authorized. The CDC-recommended allocation policy will likely involve a tiered approach based on methodologies developed similar to pandemic flu planning. Medical and first responders to include personnel likely to come into contact with COVID-19 will in the top category.

 

Q. Why is the plan phase driven and not population or hot spot focused?

A. The distribution process is phase driven to safely protect the DoD from COVID-19 as quickly as possible. In the initial phase, a limited number of sites were selected to receive vaccine. Initial sites also allow DoD to validate distribution and administration processes and structures and guide senior leader decisions to increase distribution as vaccine manufacturing and CDC allocation permits. Initial site performance will guide follow-on site identification and the scaling of DoD distribution and administration processes.

 

Q. How will DoD track personnel who receive a COVID vaccine?

A. DoD will track COVID vaccine administration through existing medical record reporting systems.

 

Q. Will the vaccine developed be shared with other countries?

A. The U.S. government is committed to working with other countries friendly to our national security to ensure safe and effective COVID-19 vaccines are developed as fast as possible. Once the needs of the American people are met, utilization of remaining vaccines and therapeutics will be distributed as a matter of national policy.

 

Q. How will the vaccine be distributed?

A. This situation continues to change, and planning will progress as more information about any authorized or approved vaccines becomes available. A safe and effective COVID-19 vaccine is a critical component of the U.S. strategy to reduce COVID-19-related illnesses, hospitalizations, and deaths and to help society function as it did before COVID-19. The goal of the U.S. government is to have enough COVID-19 vaccine doses for all people in the United States who choose to be vaccinated. Within USFK, there will be a tiered approach vaccinating those identified by DOD and CDC priority first.

 

Q. What can I do now to protect myself from getting COVID-19 since a vaccine is not yet available?

A. Continue to adherer to the 3 USFK core tenants. You should cover your mouth and nose with a mask when around others, avoid close contact with people who are sick, stay 6 feet away from others, avoid crowds, and wash your hands often. Get more information about these and other steps you can take to protect yourself and others from COVID-19.

 

Q. Will I still have to adhere to COVID-19 prevention standards if I receive a vaccine?

A. Yes. While experts learn more about the protection that COVID-19 vaccines provide under real-life conditions, it will be important for everyone to continue using all the tools available to us to help stop this pandemic, like covering your mouth and nose with a mask, washing hands often, and staying at least 6 feet away from others. Together, COVID-19 vaccination and following CDC’s recommendations for how to protect yourself and others will offer the best protection from getting and spreading COVID-19. Experts need to understand more about the protection that COVID-19 vaccines provide before deciding to change recommendations on steps everyone should take to slow the spread of the virus that causes COVID-19. Other factors, including how many people get vaccinated and how the virus is spreading in communities, will also affect this decision. We must remain vigilant to fight tonight.

 

Q. How do I report if I have a problem or bad reaction after receiving a COVID-19 vaccine?

A. Anyone experiencing having potential side effect should report to their healthcare provider/PCM or MTF immunizations clinic.  In addition, the CDC is also implementing a new smartphone-based tool called v-safe to check-in on people’s health after they receive a COVID-19 vaccine. When you receive your vaccine, you should also receive a v-safe information sheet telling you how to enroll in v-safe. If you enroll, you will receive regular text messages directing you to surveys where you can report any problems or adverse reactions you have after receiving a COVID-19 vaccine.

 

Q. Am I required to take the COVID-19 vaccine if I am identified in a high priority category?

A. There are many questions about the COVID-19 vaccine, including whether it will be mandatory for military members. Currently there are no directives that would make the COVID-19 vaccine mandatory for any DOD members. In the event of a Presidential Executive Order mandating vaccines, or the forthcoming EUA includes service guidance for mandatory vaccine, updated policy will be provided.   

 

Q. Will TRICARE beneficiaries including military retirees have access to the vaccine?

A. Yes, based on DoD prioritization. While there is limited vaccine availability, vaccination distribution prioritization will focus on those providing direct medical care, maintaining essential national security and installation functions, deploying forces, and those beneficiaries at the highest risk for developing severe illness from COVID-19. TRICARE beneficiaries empaneled at a DoD Military Treatment Facility (MTF) are eligible to receive the vaccine at a DoD MTF. TRICARE beneficiaries who receive care at DoD MTFs on a space-available basis can alternately receive vaccine through the local civilian jurisdiction.

 

Q. What is an Emergency Use Authorization (EUA)?

A. Drugs and vaccines have to be approved by the Food and Drug Administration (FDA) to ensure that only safe and effective products are available to the American public. In situations when there is good scientific reason to believe that a product is safe and is likely to treat or prevent disease, the FDA may authorize its emergency use under specific circumstances. Vaccines authorized for emergency use are offered on a voluntary basis.

 

Q. Will TRICARE beneficiaries including military retirees have access to the vaccine?

A. Yes, based on DoD prioritization. While there is limited vaccine availability, vaccination distribution prioritization will focus on those providing direct medical care, maintaining essential national security and installation functions, deploying forces, and those beneficiaries at the highest risk for developing severe illness from COVID-19. TRICARE beneficiaries empaneled at a DoD Military Treatment Facility (MTF) are eligible to receive the vaccine at a DoD MTF. TRICARE beneficiaries who receive care at DoD MTFs on a space-available basis can alternately receive vaccine through the local civilian jurisdiction. 

 

Q. What is DoD’s supporting role in Operation Warp Speed?

A. DoD's is in support of the Department of Health and Human Services and is harnessing vast DoD logistical expertise to provide the vision and intent for the distribution strategy, while working hand in hand with the CDC to leverage their planning efforts. To that end, Gen. Gustave F. Perna is the OWS chief operating officer responsible for coordination of planning, logistics, security and assurance, supply chain development, and manufacturing in support of OWS. Our unique capabilities will enable faster distribution and administration across the United States than would have otherwise been possible.

 

Q. Will DoD distribute the vaccine to the American public too?

A. Operation Warp Speed is facilitating vaccine distribution to the American public. HHS and CDC lead planning and implementation, with DoD augmenting the deliberate, comprehensive micro-planning efforts down to the state/territory (jurisdiction) level. At this time, we do not anticipate a large commitment of DoD units or personnel to support the nationwide distribution of vaccines to the US civilian population. DoD’s role is primarily planning staff augmentation and execution oversight in conjunction with and in support of the CDC. Any DoD required logistical support would be by exception and consistent with support of state responses during Defense Support to Civil Authorities.

Back to top

Share This Page